SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Author:

Kreuzberger Nina1,Hirsch Caroline1,Chai Khai Li2,Tomlinson Eve3,Khosravi Zahra1,Popp Maria4,Neidhardt Miriam1,Piechotta Vanessa1,Salomon Susanne5,Valk Sarah J6,Monsef Ina1,Schmaderer Christoph7,Wood Erica M2,So-Osman Cynthia8,Roberts David J9,McQuilten Zoe2,Estcourt Lise J10,Skoetz Nicole11

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

3. Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK

4. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Wuerzburg; Wuerzburg Germany

5. Laboratory of Experimental Immunology, Institute of Virology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

6. Jon J van Rood Center for Clinical Transfusion Research; Sanquin/Leiden University Medical Center; Leiden Netherlands

7. Department of Nephrology; Technical University of Munich, School of Medicine, Klinikum rechts der Isar; Munich Germany

8. Erasmus Medical Centre; Rotterdam Netherlands

9. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

10. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

11. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference306 articles.

1. A neutralizing monoclonal antibody for hospitalised patients with COVID-19;Lundgren;New England Journal of Medicine,2021

2. Lundgren JD Grund B Barkauskas CE Holland TL Gottlieb RL Sandkovsky U Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 medrxiv [Preprint] 2021 10.1101/2021.07.19.21260559

3. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19;Chen;New England Journal of Medicine,2020

4. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial;Gottlieb;JAMA,2021

5. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19;Chen;New England Journal of Medicine,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3